<?xml version="1.0" encoding="UTF-8"?>
<p id="Par76">Despite these overwhelming advances, challenges remain in eliminating HCV in some patient subgroups, such as subjects with decompensated cirrhosis, severe kidney disease, and in the elderly [
 <xref ref-type="bibr" rid="CR18">18</xref>]. In addition, among these vulnerable populations, also patients who have psychiatric disorders should be taken into account, for whom IFN-treatment was eluded in previous years or discontinued for severe long-term and incapacitating neuropsychiatric side effects [
 <xref ref-type="bibr" rid="CR9">9</xref>]. A certain reluctance of physicians to treat this “special group” can be attributed to concerns about poor treatment adherence or pessimism regarding HCV-treatment tolerability and/or effectiveness even in the DAA era [
 <xref ref-type="bibr" rid="CR19">19</xref>]. For all the above mentioned reasons, nowadays these patients are still lacking or delaying access to treatment and cure.
</p>
